Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077633 | 0.82 | SMN1; SMN2 (0.40) | MEN1KMT2AALDH1A1POLBMAPT | |
| SCHEMBL7073776 | 0.77 | ALDH1A1 (0.51) | KMT2AALDH1A1MAPT | |
| SCHEMBL7079205 | 0.75 | ALDH1A1 (0.47) | KMT2AALDH1A1 | |
| SCHEMBL7077638 | 0.74 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL8720282 | 0.73 | MEN1 (0.58) | MEN1KMT2AALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL7078057 | 0.73 | HSD11B1 (0.48) | MEN1KMT2AALDH1A1POLBMAPT | |
| Dimethylamine SCHEMBL27406204 | 0.72 | TP53 (0.65) | MEN1KMT2AALDH1A1MAPT | |
| Methyl Alcohol SCHEMBL27717832 | 0.72 | TP53 (0.69) | MEN1KMT2AALDH1A1POLBMAPT | |
| SCHEMBL333455 | 0.72 | TP53 (0.73) | MEN1KMT2AALDH1A1POLBMAPT | |
| SCHEMBL6903550 | 0.72 | MEN1 (0.50) | MEN1KMT2AALDH1A1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003059872-A1 | AVB3 AND AVB5 INTEGRIN ANTAGONISTS AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH AVB3 AND AVB5 INTEGRINS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059872-A1 | AVB3 AND AVB5 INTEGRIN ANTAGONISTS AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH AVB3 AND AVB5 INTEGRINS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |